{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:37:26Z","timestamp":1789616246566,"version":"build-2803163510"},"reference-count":37,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Lisata Therapeutics, Inc."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Glioblastoma multiforme (GBM) is an aggressive primary brain tumour associated with a poor prognosis despite standard-of-care treatment, including surgical resection, radiotherapy and temozolomide (TMZ) chemotherapy. Certepetide (also known as LSTA1, CEND-1) is an investigational tumour-penetrating peptide that facilitates the extravascular delivery and intratumoural penetration of co-administered immune\/chemotherapeutics; however, it has not yet been evaluated in clinical trials for the treatment of intracranial malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>LSTA1-GBM-2A is an exploratory phase 2a, double-blind, placebo-controlled, randomised, proof-of-concept investigator-initiated trial assessing the safety, tolerability and preliminary efficacy of certepetide in combination with standard-of-care TMZ, compared with TMZ with a matching placebo, in subjects with newly diagnosed GBM.<\/jats:p>\n                    <jats:p>The trial is funded by Lisata Therapeutics, sponsored by Tartu University Hospital and conducted at hospitals in Estonia and Latvia. Subjects are randomised in a 2:1 ratio. Following initial surgery and radiotherapy with concurrent TMZ, the subjects receive intravenous certepetide or placebo alongside six cycles of adjuvant TMZ treatment. The primary endpoint is overall survival. The target number of subjects is 30. The first subject was recruited in January 2024, and accrual is ongoing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study was approved by the Republic of Estonia State Agency of Medicines (17 October 2023) and the State Agency of Medicines of the Republic of Latvia (1 February 2024). The results of this study will be published in peer-reviewed journals and reported at academic conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>2023-506813-23-00.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-106094","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T13:00:40Z","timestamp":1763038840000},"page":"e106094","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["LSTA1-GBM-2A: study protocol for an exploratory phase 2a randomised controlled trial evaluating tumour-homing peptide certepetide with temozolomide in glioblastoma multiforme"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0323-913X","authenticated-orcid":false,"given":"Johannes P\u00e4rtel","family":"Truusalu","sequence":"first","affiliation":[{"name":"Tartu University Hospital, Tartu, Estonia"},{"name":"University of Tartu, Tartu, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kersti","family":"Oselin","sequence":"additional","affiliation":[{"name":"North Estonia Medical Centre, Tallinn, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Lass","sequence":"additional","affiliation":[{"name":"Tartu University Hospital, Tartu, Estonia"},{"name":"University of Tartu, Tartu, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-3578","authenticated-orcid":false,"given":"Kristen K","family":"Buck","sequence":"additional","affiliation":[{"name":"Lisata Therapeutics Inc, Basking Ridge, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1950-1692","authenticated-orcid":false,"given":"William","family":"Sietsema","sequence":"additional","affiliation":[{"name":"Lisata Therapeutics Inc, Basking Ridge, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiie","family":"Soeorg","sequence":"additional","affiliation":[{"name":"University of Tartu, Tartu, Estonia"},{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadri","family":"Toome","sequence":"additional","affiliation":[{"name":"Tartu University Hospital, Tartu, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Kaarna","sequence":"additional","affiliation":[{"name":"Tartu University Hospital, Tartu, Estonia"},{"name":"University of Tartu, Tartu, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tambet","family":"Teesalu","sequence":"additional","affiliation":[{"name":"University of Tartu, Tartu, Estonia"},{"name":"University of California Santa Barbara, Santa Barbara, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenne-Triin","family":"K\u00f5rgvee","sequence":"additional","affiliation":[{"name":"Tartu University Hospital, Tartu, Estonia"},{"name":"University of Tartu, Tartu, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"2025120413271354000_15.11.e106094.1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou087"},{"key":"2025120413271354000_15.11.e106094.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0603-6"},{"key":"2025120413271354000_15.11.e106094.3","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106"},{"key":"2025120413271354000_15.11.e106094.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330"},{"key":"2025120413271354000_15.11.e106094.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70025-7"},{"key":"2025120413271354000_15.11.e106094.6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"2025120413271354000_15.11.e106094.7","doi-asserted-by":"crossref","first-page":"iii93","DOI":"10.1093\/annonc\/mdu050","article-title":"High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25 Suppl 3","author":"Stupp","year":"2014","journal-title":"Ann Oncol"},{"key":"2025120413271354000_15.11.e106094.8","unstructured":"Sharp M , Dohme BV . Summary of product characteristics - temodal (temozolomide). Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/temodal-epar-product-information_en.pdf [Accessed 23 Apr 2025]."},{"key":"2025120413271354000_15.11.e106094.9","doi-asserted-by":"crossref","first-page":"174580","DOI":"10.1016\/j.ejphar.2021.174580","article-title":"Comprehensive pharmacogenomics characterization of temozolomide response in gliomas","volume":"912","author":"Tong","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"2025120413271354000_15.11.e106094.10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41397-019-0107-z","article-title":"ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide","volume":"20","author":"Malmstr\u00f6m","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"2025120413271354000_15.11.e106094.11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/jpm13020188","article-title":"Tumor Microenvironment and Genes Affecting the Prognosis of Temozolomide-Treated Glioblastoma","volume":"13","author":"Jang","year":"2023","journal-title":"J Pers Med"},{"key":"2025120413271354000_15.11.e106094.12","doi-asserted-by":"publisher","DOI":"10.1126\/science.1183057"},{"key":"2025120413271354000_15.11.e106094.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.10.013"},{"key":"2025120413271354000_15.11.e106094.14","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2748"},{"key":"2025120413271354000_15.11.e106094.15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0908201106"},{"key":"2025120413271354000_15.11.e106094.16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5105"},{"key":"2025120413271354000_15.11.e106094.17","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-200108000-00022"},{"key":"2025120413271354000_15.11.e106094.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185065","article-title":"Neuropilin-1 modulates TGF\u03b2 signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy","volume":"12","author":"Kwiatkowski","year":"2017","journal-title":"PLoS One"},{"key":"2025120413271354000_15.11.e106094.19","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.49"},{"key":"2025120413271354000_15.11.e106094.20","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jconrel.2014.12.039","article-title":"Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy","volume":"200","author":"Sha","year":"2015","journal-title":"J Control Release"},{"key":"2025120413271354000_15.11.e106094.21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0395"},{"key":"2025120413271354000_15.11.e106094.22","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200910104"},{"key":"2025120413271354000_15.11.e106094.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.03.008"},{"key":"2025120413271354000_15.11.e106094.24","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1172\/JCI93955","article-title":"Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier","volume":"127","author":"Ruoslahti","year":"2017","journal-title":"J Clin Invest"},{"key":"2025120413271354000_15.11.e106094.25","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.3892\/mmr.2017.6419","article-title":"iRGD as a tumor\u2011penetrating peptide for cancer therapy (Review)","volume":"15","author":"Yin","year":"2017","journal-title":"Mol Med Rep"},{"key":"2025120413271354000_15.11.e106094.26","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0366"},{"key":"2025120413271354000_15.11.e106094.27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21858-1","article-title":"Tumor-penetrating therapy for \u03b25 integrin-rich pancreas cancer","volume":"12","author":"Hurtado de Mendoza","year":"2021","journal-title":"Nat Commun"},{"key":"2025120413271354000_15.11.e106094.28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1114518108"},{"key":"2025120413271354000_15.11.e106094.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2013.03.036"},{"key":"2025120413271354000_15.11.e106094.30","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S2468-1253(22)00167-4","article-title":"Dual \u03b1V-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study","volume":"7","author":"Dean","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025120413271354000_15.11.e106094.31","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e16290","article-title":"A phase Ib\/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics\/pharmacodynamics of \u03b1v\u03b23\/5 integrin and neuropilin-1 targeting peptide LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma","volume":"41","author":"Xu","year":"2023","journal-title":"JCO"},{"key":"2025120413271354000_15.11.e106094.32","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1200\/JCO.2025.43.4_suppl.746","article-title":"Immunotherapy engagement in pancreatic adenocarcinoma: Provisional results of iLSTA study\u2014 Durvalumab, LSTA1 (certepetide), gemcitabine, and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma","volume":"43","author":"Dean","year":"2025","journal-title":"JCO"},{"key":"2025120413271354000_15.11.e106094.33","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2025.43.4_suppl.728","article-title":"AGITG ASCEND: Randomised, double-blind phase II study of certepetide or placebo added to gemcitabine plus nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma: Initial results","volume":"43","author":"Dean","year":"2025","journal-title":"JCO"},{"key":"2025120413271354000_15.11.e106094.34","unstructured":"National Cancer Institute . Common terminology criteria for adverse events (CTCAE). 2017. Available: https:\/\/www.meddra.org\/ [Accessed 23 Apr 2025]."},{"key":"2025120413271354000_15.11.e106094.35","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"2025120413271354000_15.11.e106094.36","unstructured":"Sealed envelope. Available: https:\/\/www.sealedenvelope.com\/ [Accessed 23 Apr 2025]."},{"key":"2025120413271354000_15.11.e106094.37","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-016-0507-6"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-106094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:29:16Z","timestamp":1764883756000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-106094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,13]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjopen-2025-106094"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-106094","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}